These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy. Lange F; Hörnschemeyer J; Kirschstein T Cells; 2021 May; 10(5):. PubMed ID: 34067762 [TBL] [Abstract][Full Text] [Related]
4. Perampanel, an antagonist of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors, for the treatment of epilepsy: studies in human epileptic brain and nonepileptic brain and in rodent models. Zwart R; Sher E; Ping X; Jin X; Sims JR; Chappell AS; Gleason SD; Hahn PJ; Gardinier K; Gernert DL; Hobbs J; Smith JL; Valli SN; Witkin JM J Pharmacol Exp Ther; 2014 Oct; 351(1):124-33. PubMed ID: 25027316 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of calcium-permeable and calcium-impermeable AMPA receptors by perampanel in rat brain neurons. Barygin OI Neurosci Lett; 2016 Oct; 633():146-151. PubMed ID: 27663136 [TBL] [Abstract][Full Text] [Related]
6. Perampanel Inhibits Neuroblastoma Cell Proliferation Through Down-regulation of AKT and ERK Pathways. Nozawa A; Ozeki M; Matsuoka M; Nakama M; Yasue S; Endo S; Kawamoto N; Ohnishi H; Fukao T Anticancer Res; 2019 Jul; 39(7):3595-3599. PubMed ID: 31262884 [TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of anti-seizure medications on ionotropic glutamate receptors: special focus on AMPA receptor subunits. Fukushima K; Hatanaka K; Sagane K; Ido K Epilepsy Res; 2020 Nov; 167():106452. PubMed ID: 32911258 [TBL] [Abstract][Full Text] [Related]
9. The discovery and development of perampanel for the treatment of epilepsy. Hanada T Expert Opin Drug Discov; 2014 Apr; 9(4):449-58. PubMed ID: 24559052 [TBL] [Abstract][Full Text] [Related]
10. Experience of Low Dose Perampanel to Add-on in Glioma Patients with Levetiracetam-uncontrollable Epilepsy. Chonan M; Saito R; Kanamori M; Osawa SI; Watanabe M; Suzuki H; Nakasato N; Tominaga T Neurol Med Chir (Tokyo); 2020 Jan; 60(1):37-44. PubMed ID: 31748440 [TBL] [Abstract][Full Text] [Related]
11. The AMPA receptor antagonist NBQX exerts anti-seizure but not antiepileptogenic effects in the intrahippocampal kainate mouse model of mesial temporal lobe epilepsy. Twele F; Bankstahl M; Klein S; Römermann K; Löscher W Neuropharmacology; 2015 Aug; 95():234-42. PubMed ID: 25839899 [TBL] [Abstract][Full Text] [Related]
12. AMPA receptors and perampanel behind selected epilepsies: current evidence and future perspectives. Di Bonaventura C; Labate A; Maschio M; Meletti S; Russo E Expert Opin Pharmacother; 2017 Nov; 18(16):1751-1764. PubMed ID: 29023170 [TBL] [Abstract][Full Text] [Related]
13. Perampanel: Does it have broad-spectrum potential? Potschka H; Trinka E Epilepsia; 2019 Mar; 60 Suppl 1():22-36. PubMed ID: 29953584 [TBL] [Abstract][Full Text] [Related]
14. Introduction: Perampanel--new mode of action and new option for patients with epilepsy. Steinhoff BJ Epilepsia; 2014 Jan; 55 Suppl 1():1-2. PubMed ID: 24400689 [TBL] [Abstract][Full Text] [Related]
15. Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management. Vecht C; Royer-Perron L; Houillier C; Huberfeld G Curr Pharm Des; 2017; 23(42):6464-6487. PubMed ID: 29076421 [TBL] [Abstract][Full Text] [Related]
16. PerSurge (NOA-30) phase II trial of perampanel treatment around surgery in patients with progressive glioblastoma. Heuer S; Burghaus I; Gose M; Kessler T; Sahm F; Vollmuth P; Venkataramani V; Hoffmann D; Schlesner M; Ratliff M; Hopf C; Herrlinger U; Ricklefs F; Bendszus M; Krieg SM; Wick A; Wick W; Winkler F BMC Cancer; 2024 Jan; 24(1):135. PubMed ID: 38279087 [TBL] [Abstract][Full Text] [Related]
17. The Noncompetitive AMPAR Antagonist Perampanel Abrogates Brain Endothelial Cell Permeability in Response to Ischemia: Involvement of Claudin-5. Lv JM; Guo XM; Chen B; Lei Q; Pan YJ; Yang Q Cell Mol Neurobiol; 2016 Jul; 36(5):745-53. PubMed ID: 26306919 [TBL] [Abstract][Full Text] [Related]
18. Perampanel and decanoic acid show synergistic action against AMPA receptors and seizures. Augustin K; Williams S; Cunningham M; Devlin AM; Friedrich M; Jayasekera A; Hussain MA; Holliman D; Mitchell P; Jenkins A; Chen PE; Walker MC; Williams RSB Epilepsia; 2018 Nov; 59(11):e172-e178. PubMed ID: 30324610 [TBL] [Abstract][Full Text] [Related]
19. The AMPA receptor antagonist perampanel suppresses epileptic activity in human focal cortical dysplasia. Brito da Silva A; Pennifold J; Henley B; Chatterjee K; Bateman D; Whittaker RW; Joshi A; Kumar H; Nicholson C; Baker MR; Greenhill SD; Walsh R; Seri S; Jones RSG; Woodhall GL; Cunningham MO Epilepsia Open; 2022 Sep; 7(3):488-495. PubMed ID: 34653311 [TBL] [Abstract][Full Text] [Related]